Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options
NCT00144287
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
255
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Tipranavir/Ritonavir
Sponsor
Boehringer Ingelheim